Sera Prognostics, Inc. (NASDAQ:SERA) Insider Robert Gardner Harrison Sells 14,209 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now directly owns 116,837 shares of the company’s stock, valued at approximately $863,425.43. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total transaction of $14,648.08.

Sera Prognostics Stock Up 0.6 %

Shares of NASDAQ:SERA traded up $0.04 during midday trading on Tuesday, reaching $6.37. 134,610 shares of the company were exchanged, compared to its average volume of 143,614. The firm has a market cap of $215.13 million, a PE ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The stock has a fifty day simple moving average of $7.44 and a two-hundred day simple moving average of $7.31.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the company earned ($0.23) earnings per share. As a group, analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC boosted its position in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics during the second quarter worth $68,000. SG Americas Securities LLC bought a new position in Sera Prognostics in the third quarter valued at $78,000. Prime Capital Investment Advisors LLC bought a new position in Sera Prognostics in the third quarter valued at $104,000. Finally, Jane Street Group LLC increased its stake in Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after buying an additional 2,826 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.